Despite advancements in insulin therapy (ultra-rapid and ultra-long-acting analogues) and technological breakthroughs (insulin pump, automated-insulin delivering systems), some patients living with type 1 diabetes (T1D) still experience significant glycemic variability, severe hypoglycemic episodes, and high glycemic variability. The gene discussed is INS; the disease is type 1 diabetes mellitus.